Ikena Oncology (NASDAQ:IKNA – Get Free Report) and Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Risk and Volatility
Ikena Oncology has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Institutional and Insider Ownership
86.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 70.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 6.0% of Ikena Oncology shares are owned by insiders. Comparatively, 11.5% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ikena Oncology||$15.62 million||10.99||-$68.76 million||($1.70)||-2.39|
|Tarsus Pharmaceuticals||$25.82 million||18.51||-$62.09 million||($3.38)||-4.33|
Tarsus Pharmaceuticals has higher revenue and earnings than Ikena Oncology. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks.
This table compares Ikena Oncology and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Ikena Oncology and Tarsus Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ikena Oncology presently has a consensus price target of $14.00, suggesting a potential upside of 244.83%. Tarsus Pharmaceuticals has a consensus price target of $46.40, suggesting a potential upside of 216.72%. Given Ikena Oncology’s higher possible upside, research analysts plainly believe Ikena Oncology is more favorable than Tarsus Pharmaceuticals.
About Ikena Oncology
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.